Pharmaceutical Contract Manufacturing Market Size, Share, By Type (Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development & Manufacturing, and Secondary Packaging), and By Region - Trends, Analysis and Forecast till 2034

Report Code: PMI410020 | Publish Date: August 2023 | No. of Pages: 175

Global Pharmaceutical Contract Manufacturing Market Companies

  • Recipharm AB
  • Jubilant Life Sciences Ltd.
  • Patheon Inc.
  • Boehringer Ingelheim
  • Pfizer CentreSource
  • Aenova Group
  • Famar S.A.
  • Baxter BioPharma Solutions
  • Lonza Group

Recent News:

  • In December 2022, RedHill Biopharma confirmed that Recipharm will continue to commercially manufacture Talicia, a drug designed to treat H. pylori infection, until 2026. RedHill and Recipharm have been collaborating closely since in 2015, jointly developed and manufactured Talicia, including the release of capsules containing omeprazole magnesium, amoxicillin and rifabutin (10 mg/250 mg/12.5 mg).
  • In January 2020, Celltrion, a  Korean biosimilar manufacturer, revealed plans to invest $514 million over five years to build a new facility in Wuhan, China. This modern bio-mill is expected to have a significant capacity of 120,000 liters.